Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
iVAC-CLL01 individualized peptide vaccination in CLL/SLL
2015-005817-61Phase 2Terminated
- Sponsor
- University Hospital Tübingen
- Start
- Apr 2016
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of individualized peptide vaccine in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by University Hospital Tübingen. Primary endpoint: Induction of peptide-specific T cell responses. Started Apr 2016; status: terminated.
02
Drugs
individualized peptide vaccine
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2015-005817-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005817-61.